These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311 [TBL] [Abstract][Full Text] [Related]
4. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119 [TBL] [Abstract][Full Text] [Related]
5. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. Kim I; Ryu YS; Kwak HJ; Ahn SY; Oh JL; Yancopoulos GD; Gale NW; Koh GY FASEB J; 2002 Jul; 16(9):1126-8. PubMed ID: 12039842 [TBL] [Abstract][Full Text] [Related]
6. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. He S; Kumar SR; Zhou P; Krasnoperov V; Ryan SJ; Gill PS; Hinton DR Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):543-52. PubMed ID: 19696168 [TBL] [Abstract][Full Text] [Related]
13. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Masood R; Xia G; Smith DL; Scalia P; Still JG; Tulpule A; Gill PS Blood; 2005 Feb; 105(3):1310-8. PubMed ID: 15471957 [TBL] [Abstract][Full Text] [Related]
14. EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. Takyar FM; Tonna S; Ho PW; Crimeen-Irwin B; Baker EK; Martin TJ; Sims NA J Bone Miner Res; 2013 Apr; 28(4):912-25. PubMed ID: 23165727 [TBL] [Abstract][Full Text] [Related]
15. Altered expression patterns of EphrinB2 and EphB2 in human umbilical vessels and congenital venous malformations. Diehl S; Bruno R; Wilkinson GA; Loose DA; Wilting J; Schweigerer L; Klein R Pediatr Res; 2005 Apr; 57(4):537-44. PubMed ID: 15718372 [TBL] [Abstract][Full Text] [Related]
16. EphB4 as a therapeutic target in mesothelioma. Liu R; Ferguson BD; Zhou Y; Naga K; Salgia R; Gill PS; Krasnoperov V BMC Cancer; 2013 May; 13():269. PubMed ID: 23721559 [TBL] [Abstract][Full Text] [Related]
17. Shear stress increases expression of the arterial endothelial marker ephrinB2 in murine ES cells via the VEGF-Notch signaling pathways. Masumura T; Yamamoto K; Shimizu N; Obi S; Ando J Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2125-31. PubMed ID: 19797707 [TBL] [Abstract][Full Text] [Related]
18. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Abéngozar MA; de Frutos S; Ferreiro S; Soriano J; Perez-Martinez M; Olmeda D; Marenchino M; Cañamero M; Ortega S; Megias D; Rodriguez A; Martínez-Torrecuadrada JL Blood; 2012 May; 119(19):4565-76. PubMed ID: 22446484 [TBL] [Abstract][Full Text] [Related]